A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
A Randomized, Open Label Study Comparing the Effect of Mircera and Epoetin Beta on Hemoglobin Response in Patients With Chronic Kidney Disease Who Are on Dialysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100050
-
Beijing, China, 100853
-
Beijing, China, 10029
-
Chengdu, China, 610072
-
Guangzhou, China
-
Guangzhou, China, 510515
-
Hangzhou, China, 310003
-
Nanjing, China, 210009
-
Shanghai, China, 200032
-
Shanghai, China, 200025
-
Shanghai, China, 200040
-
Shanghai, China, 200001
-
Shanghai, China, 200003
-
-
-
-
-
Hong Kong, Hong Kong
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients, >=18 years of age;
- chronic renal anemia requiring dialysis;
- maintenance hemodialysis or peritoneal dialysis for >=2 weeks before and during screening;
- adequate iron status.
Exclusion Criteria:
- previous epoetin treatment within 8 weeks prior to screening;
- failing renal graft in place;
- bleeding episode necessitating transfusion within 8 weeks prior to screening;
- poorly controlled hypertension;
- previous treatment with Mircera.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
0.4 micrograms/kg iv every 2 weeks
|
|
Active Comparator: 2
|
As prescribed, 3 times weekly
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hb response rate
Time Frame: Weeks 0-24
|
Weeks 0-24
|
|
Change in Hb concentration between baseline and evaluation period
Time Frame: Months 4-6
|
Months 4-6
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Hb over time
Time Frame: Throughout study
|
Throughout study
|
|
Time to Hb response
Time Frame: Throughout study
|
Throughout study
|
|
RBC transfusions
Time Frame: Weeks 0-24
|
Weeks 0-24
|
|
AEs, laboratory parameters, vital signs
Time Frame: Throughout study
|
Throughout study
|
|
Serum concentration of Mircera
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ML20680
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.